المؤلفون: Sakemura RL; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Manriquez Roman C; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN., Horvei P; T Cell Engineering, Mayo Clinic, Rochester, MN.; Pediatric Bone Marrow Transplant and Cellular Therapy, UPMC Children's Hospital of Pittsburgh, PA., Siegler EL; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Girsch JH; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN., Sirpilla OL; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN., Stewart CM; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN., Yun K; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN., Can I; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN., Ogbodo EJ; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Adada MM; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Bezerra ED; T Cell Engineering, Mayo Clinic, Rochester, MN., Kankeu Fonkoua LA; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Hefazi M; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Ruff MW; T Cell Engineering, Mayo Clinic, Rochester, MN.; Department of Neurology, Mayo Clinic, Rochester, MN., Kimball BL; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Mai LK; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Huynh TN; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN., Nevala WK; Department of Immunology, Mayo Clinic, Rochester, MN., Ilieva K; Morphosys AG, Planegg, Germany., Augsberger C; Morphosys AG, Planegg, Germany., Patra-Kneuer M; Morphosys AG, Planegg, Germany., Schanzer J; Morphosys AG, Planegg, Germany., Endell J; Morphosys AG, Planegg, Germany., Heitmüller C; Morphosys AG, Planegg, Germany., Steidl S; Morphosys AG, Planegg, Germany., Parikh SA; Division of Hematology, Mayo Clinic, Rochester, MN., Ding W; Division of Hematology, Mayo Clinic, Rochester, MN., Kay NE; Division of Hematology, Mayo Clinic, Rochester, MN., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN., Kenderian SS; T Cell Engineering, Mayo Clinic, Rochester, MN.; Division of Hematology, Mayo Clinic, Rochester, MN.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.; Department of Immunology, Mayo Clinic, Rochester, MN.

المصدر: Blood [Blood] 2024 Jan 18; Vol. 143 (3), pp. 258-271.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy* , Antibodies, Monoclonal, Humanized*, Therapeutic Index ; Antigens, CD19 ; Immunotherapy, Adoptive/methods

المؤلفون: Shanafelt TD; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Wang XV; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Kay NE; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Hanson CA; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., O'Brien S; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Barrientos J; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Jelinek DF; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Braggio E; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Leis JF; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Zhang CC; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Coutre SE; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Barr PM; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Cashen AF; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Mato AR; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Singh AK; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Mullane MP; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Little RF; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Erba H; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Stone RM; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Litzow M; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.)., Tallman M; From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.).

المصدر: The New England journal of medicine [N Engl J Med] 2019 Aug 01; Vol. 381 (5), pp. 432-443.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy*, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy , Pyrazoles/*administration & dosage , Pyrimidines/*administration & dosage , Rituximab/*administration & dosage, Adenine/analogs & derivatives ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Female ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Piperidines ; Progression-Free Survival ; Pyrazoles/adverse effects ; Pyrimidines/adverse effects ; Rituximab/adverse effects ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives

المؤلفون: Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Memorial-Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: jsoumerai@mgh.harvard.edu., Ni A; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Darif M; Janssen Pharmaceuticals, Horsham, PA, USA., Londhe A; Janssen Pharmaceuticals, Horsham, PA, USA., Xing G; Gilead Sciences, Seattle, WA, USA., Mun Y; Genentech, South San Francisco, CA, USA., Kay NE; Mayo Clinic, Rochester, MN, USA., Shanafelt TD; Mayo Clinic, Rochester, MN, USA; Stanford University Medical Center, Stanford, CA, USA., Rabe KG; Mayo Clinic, Rochester, MN, USA., Byrd JC; Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Chanan-Khan AA; Mayo Clinic, Jacksonville, FL, USA., Furman RR; Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA., Hillmen P; St James's University Hospital, Leeds, UK., Jones J; Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Seymour JF; Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia., Sharman JP; Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA., Ferrante L; Janssen Pharmaceuticals, Horsham, PA, USA., Mobasher M; Genentech, South San Francisco, CA, USA., Stark T; Genentech, South San Francisco, CA, USA., Reddy V; Pharmacyclics, Sunnyvale, CA, USA., Dreiling LK; Gilead Sciences, Seattle, WA, USA., Bhargava P; Gilead Sciences, Seattle, WA, USA., Howes A; Janssen Pharmaceuticals, Horsham, PA, USA., James DF; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Zelenetz AD; Memorial-Sloan Kettering Cancer Center, New York, NY, USA.

المصدر: The Lancet. Haematology [Lancet Haematol] 2019 Jul; Vol. 6 (7), pp. e366-e374. Date of Electronic Publication: 2019 May 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy*, Antineoplastic Agents/*therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy, Adenine/analogs & derivatives ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Databases, Factual ; Female ; Hemoglobins/analysis ; Humans ; L-Lactate Dehydrogenase/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Piperidines ; Prognosis ; Proportional Hazards Models ; Purines/therapeutic use ; Pyrazoles/therapeutic use ; Pyrimidines/therapeutic use ; Quinazolinones/therapeutic use ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Risk Factors ; Sulfonamides/therapeutic use ; Survival Rate ; beta 2-Microglobulin/blood

المؤلفون: Brown JR; Jennifer R. Brown, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Neil E. Kay, Mayo Clinic, Rochester, MN., Kay NE; Jennifer R. Brown, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Neil E. Kay, Mayo Clinic, Rochester, MN.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Sep 10; Vol. 35 (26), pp. 2989-2992. Date of Electronic Publication: 2017 Jul 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Immunotherapy/*methods , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy, Antineoplastic Agents, Immunological/adverse effects ; Clinical Decision-Making ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/mortality ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Patient Selection ; Progression-Free Survival ; Risk Factors ; Time Factors ; Treatment Outcome

المؤلفون: Shanafelt T; Mayo Clinic, Rochester, Minnesota., Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS

المصدر: Cancer [Cancer] 2013 Nov 01; Vol. 119 (21), pp. 3788-96. Date of Electronic Publication: 2013 Aug 06.

نوع المنشور: Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Immunotherapy/*methods , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy, Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antibodies, Monoclonal, Murine-Derived/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cohort Studies ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Female ; Humans ; Immunotherapy/adverse effects ; Male ; Middle Aged ; Neoadjuvant Therapy ; Pentostatin/administration & dosage ; Pentostatin/adverse effects ; Rituximab ; Treatment Outcome

المؤلفون: Shanafelt TD; Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA. hanafelt.tait@mayo.edu., Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE

المصدر: Blood [Blood] 2013 May 16; Vol. 121 (20), pp. 4137-41. Date of Electronic Publication: 2013 Mar 14.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE

مواضيع طبية MeSH: Consolidation Chemotherapy* , Immunotherapy*/methods, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Immunological Synapses/*physiology , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy , T-Lymphocytes/*immunology , Thalidomide/*analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Cohort Studies ; Combined Modality Therapy ; Humans ; Immunological Synapses/drug effects ; Lenalidomide ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Leukemia, Lymphocytic, Chronic, B-Cell/physiopathology ; Neoadjuvant Therapy ; Recovery of Function/drug effects ; Recovery of Function/immunology ; Retrospective Studies ; T-Lymphocytes/drug effects ; T-Lymphocytes/pathology ; Thalidomide/administration & dosage ; Time Factors ; Treatment Outcome

المؤلفون: Kay NE; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kay.neil@mayo.edu, O'Brien SM, Pettitt AR, Stilgenbauer S

المصدر: Leukemia [Leukemia] 2007 Sep; Vol. 21 (9), pp. 1885-91. Date of Electronic Publication: 2007 Jun 14.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0887-6924 (Print) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers, Tumor* , Immunotherapy*, Leukemia, Lymphocytic, Chronic, B-Cell/*epidemiology , Leukemia, Lymphocytic, Chronic, B-Cell/*therapy, Humans ; Prognosis ; Risk Factors

المؤلفون: Zent CS; Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. zent.clive@mayo.edu, Kay NE

المصدر: Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2004 Feb; Vol. 2 (2), pp. 107-13.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Millennium Medical Pub Country of Publication: United States NLM ID: 101167661 Publication Model: Print Cited Medium: Internet ISSN: 1543-0790 (Print) Linking ISSN: 15430790 NLM ISO Abbreviation: Clin Adv Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy*, Antibodies, Monoclonal/*therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy, Alemtuzumab ; Animals ; Antibodies, Anti-Idiotypic/immunology ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal, Murine-Derived ; Antibodies, Neoplasm/administration & dosage ; Antibodies, Neoplasm/adverse effects ; Antibodies, Neoplasm/immunology ; Antibodies, Neoplasm/pharmacology ; Antibodies, Neoplasm/therapeutic use ; Antibody-Dependent Cell Cytotoxicity ; Antigens, CD/immunology ; Antigens, Neoplasm/immunology ; Autoimmune Diseases/etiology ; Disease Management ; Disease Progression ; Drug Resistance, Neoplasm ; Humans ; Leukopenia/etiology ; Mice ; Neoplasm Proteins/immunology ; Rats ; Risk ; Rituximab ; Tumor Lysis Syndrome/etiology

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.